BLOEMEN PHARMA SL
Company details
- Active NIF/CIF: B42643270
-
-
-
-
Address: C/ TOMAS LUIS DE VICTORIA 11 2ª - DESPACHO 6, ELCH (ELCHE).
-
-
Featured products:
More information on BLOEMEN PHARMA SL
-
11/04/2022 | BORME act no.: 162017 | Register: ALICANTE/ALACANTCambio de domicilio social
-
28/02/2022 | BORME act no.: 87146 | Register: ALICANTE/ALACANTReducción de capital
-
02/06/2021 | BORME act no.: 264650 | Register: ALICANTE/ALACANTAmpliación de capital
-
02/06/2021 | BORME act no.: 264650 | Register: ALICANTE/ALACANTModificaciones estatutarias
-
02/06/2021 | BORME act no.: 264650 | Register: ALICANTE/ALACANTPágina web de la sociedad
-
07/01/2021 | BORME act no.: 2793 | Register: ALICANTEReducción de capital
-
07/08/2019 | BORME act no.: 344956 | Register: ALICANTEConstitución
-
07/08/2019 | BORME act no.: 344956 | Register: ALICANTENombramientos
Other information
The CIF assigned to BLOEMEN PHARMA SL is B42643270, and its current commercial status is active. The company is engaged in economic activities within the CNAE 4631 - Wholesale of fruit and vegetables. As for its SIC classification, it is -.
The company BLOEMEN PHARMA SL has a team of Between 1 and 9 employees and reports annual revenues of less than 2 million euros. Registered in the Mercantile Registry of Alicante/alacant, it has a total of 1 registered positions. Its most recent announcement in the Borme was published on 11/04/2022, and the last deposit of its annual accounts corresponds to the year 2021.
To find out more contact details of BLOEMEN PHARMA SL, such as telephone number, address, or website, you can consult the Company Data module.
If you want to obtain more information about BLOEMEN PHARMA SL, you can review one of the available financial reports, the company's Annual Accounts, or check for any default incidents in the RAI delinquency file.
The financial, commercial, and legal information of BLOEMEN PHARMA SL comes from official sources and is constantly updated.
Do you want to know more about BLOEMEN PHARMA SL??
Find out more about this company by consulting these reports: